Disclosure Of Effect Of Changes In Foreign Exchange Rates [Text Block]

Ascelia Pharma - Filing #678716

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31
Disclosure of effect of changes in foreign exchange rates [text block]	—	—	Not	—	—	—	—	—	—	—	—	—	—	—	—	—
Reserve of exchange differences on translation	—	—	—	671,000 SEK	—	—	—	—	972,000 SEK	—	—	—	—	—	—	—
Disclosure of information when currency is not exchangeable into another currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of information when foreign operation’s functional currency is not exchangeable into presentation currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [abstract]
Disclosure of summarised financial information about foreign operation [line items]
Non-current assets	—	—	—	58 135 SEK	—	—	—	—	57 700 SEK	—	—	—	—	—	—	—
Current assets	—	—	—	28 937 SEK	—	—	—	—	160 869 SEK	—	—	—	—	—	—	—
Non-current liabilities	—	—	—	176,000 SEK	—	—	—	—	193,000 SEK	—	—	—	—	—	—	—
Current liabilities	—	—	—	12 568 SEK	—	—	—	—	37 518 SEK	—	—	—	—	—	—	—
Revenue	—	—	- SEK	—	—	—	—	—	—	—	—	- SEK	—	—	—	—
Profit (loss)	- SEK	- SEK	109 288 SEK	—	- SEK	109 288 SEK	109 288 SEK	- SEK	—	- SEK	131 223 SEK	131 223 SEK	131 223 SEK	- SEK	- SEK	- SEK
Other comprehensive income	—	—	301,000 SEK	—	—	—	—	—	—	—	—	718,000 SEK	—	—	—	—
Comprehensive income	- SEK	- SEK	109 589 SEK	—	- SEK	109 288 SEK	109 589 SEK	301,000 SEK	—	- SEK	130 504 SEK	130 504 SEK	131 223 SEK	- SEK	718,000 SEK	- SEK